Late-life depression (LLD) is closely related to the aging process and is often accompanied by various somatic diseases, significantly affecting the quality of life in older adults. The senescence-associated secretory phenotype (SASP) refers to multiple factors released by senescent cells, including pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases. In recent years, SASP has gained increasing attention due to its role in various physiological and pathological process by regulating the cellular microenvironment. This review summarizes the clinical research on SASP in LLD, explores its mechanisms of action and therapeutic potential, and aims to deepen the understanding of SASP in the pathogenesis of LLD and provide new insights for diagnosing and treating LLD.

Late-life depression (LLD) is closely related to the aging process and is often accompanied by various somatic diseases, significantly affecting the quality of life in older adults. The senescence-associated secretory phenotype (SASP) refers to multiple factors released by senescent cells, including pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases. In recent years, SASP has gained increasing attention due to its role in various physiological and pathological process by regulating the cellular microenvironment. This review summarizes the clinical research on SASP in LLD, explores its mechanisms of action and therapeutic potential, and aims to deepen the understanding of SASP in the pathogenesis of LLD and provide new insights for diagnosing and treating LLD.

Emotional task is one of the main methods to study the attention bias and emotional function of affective disorder.Functional near-infrared spectroscopy(fNIRS)studies based on emotional tasks in patients with affective disorders have shown that facial emotion recognition task,the emotional stroop effect,and the emotion induction task combined with fNIRS technology have clinical value in the diagnosis and treatment of affective disorders.The defects of attention function and emotional processing in patients with affective disorders are related to abnormal activation of the left prefrontal cortex,especially the differences in brain activation patterns are related to depressive symptoms in patients with depressive disorders.The future direction of using fNIRS to study emotional tasks is to combine a variety of neuroimaging methods to conduct large-sample longitudinal cohort studies to obtain more objective bases for diagnosis and treatment,and to compare the differences in activation areas of different emotional stimulation materials.

Attenuated psychosis syndrome(APS)is a clinical disorder associated with a high risk of psychosis.Patients during this period typically exhibit multidimensional neurocognitive and social cognitive impairment.Cognitive impairment in APS patients is associated with structural and functional abnormalities in the frontal,temporal and subcortical brain regions.At present,drug therapy,psychotherapy,nutritional therapy and computer cognitive training are mainly used to improve the cognitive function of APS patients.In the future,we could comprehensively utilize brain imaging,electrophysiology,and molecular imaging to deeply explore the neuropathological mechanism of APS cognitive impairment,and combine computer,virtual reality,and artificial intelligence to develop new cognitive function intervention procedures,in order to achieve APS precise prevention and treatment.

Objective:To explore the relationship between the clinical outcome of emotional symptoms and cognitive performance and related cerebral oxygenated hemoglobin in adolescents with depression.Methods:Through subject recruitment, 46 adolescent patients with depression (patient group) from the First Hospital of Shanxi Medical University were selected as the subjects for this study from December 2020 to December 2021, including 8 males and 38 females, aged 12-18 (15.7±2.3) years old. All patients received sertraline treatment for 8 weeks and were further followed into responders ( n=24) and non-responders ( n=22) according to the outcome of emotional symptoms. In the meantime, 51 healthy controls (control group) were enrolled, including 7 males and 44 females, aged 12-18 (16.1±1.5) years old. The repeatable battery for the assessment of neuropsychological status (RBANS) was conducted to measure the multi-dimensional neurocognitive performance, and the functional near-infrared spectroscopy (fNIRS) was used to assess changes in the concentration of oxyhemoglobin (HBO) during the verbal fluency test. The differences were compared in multi-dimensional cognitive performance and cerebral HBO level between each patient group and control group and between responders and non-responders. The changes were analyzed in cognitive performance and cerebral HBO level after intervention in responders and non-responders. Results:At baseline, compared to the control group, the patient group performed decreased scores of RBANS, immediate memory, speech function, attention, and delayed memory (88.0 (82.8, 100.0) M ( Q1, Q3) vs. 100.0 (90.0, 110.0) scores; 78.0 (73.0, 87.8) vs.85.0 (78.0, 94.0) scores; (84.4±16.1) vs. (95.7±15.7) scores; 106.0 (99.5, 115.0) vs.118.0 (109.0, 128.0) scores; 94.0 (84.5, 99.0) vs.97.0 (91.0, 101.0) scores), and lower HBO levels in 7 channels (all P<0.05). Compared to responders, non-responders showed more severe impairment of visual-spatial and attention performance (103.9±11.0 vs. 94.4±16.7 scores; 112.5±12.1 vs. 98.0±21.2 scores) ( t=2.30 or 2.87; all P<0.05). After treatment, the scores of RBANS and immediate memory improved significantly in responders (98.8±11.2 vs. 93.0±9.7 scores; 95.2±13.8 vs.83.0±14.6 scores) ( t=-3.00 or-4.97; both P<0.05), but the scores of attention and the HBO level of two channels in the prefrontal cortex were still significantly lower than those of the control group (Z=2.27, 3.02 or 3.04; all P<0.05). Besides, there were no significant differences in the scores of immediate memory and the HBO levels of 3 channels in the temporal lobe between the no-responders and the control group (all P>0.05). Conclusion:Immediate memory injure, attention injure and HBO levels of frontal-temporal lobes may be independent of emotional symptoms among adolescents with depression.

Cognitive impairment is one of the core features of schizophrenia and severely affects the prognosis of the disorder. Improving cognitive impairment is of great significance for alleviating symptoms, preventing relapses, enhancing the quality of life, and reducing the social burden in patients with schizophrenia. Based on the "Guidelines for the Assessment of Cognitive Impairment in Schizophrenia" published by the European Psychiatric Association in 2022, the article focuses on the intervention and management of cognitive impairment in schizophrenia patients following a systematic assessment, while also considering the specific context of practice in China. This paper reviews recent progress in cognitive impairment interventions for schizophrenia, providing clinical guidance across three key aspects: pharmacotherapy, physical therapy, and psychotherapy. Other interventions are also discussed. Additionally, it addresses the existing challenges and unresolved issues, aiming to provide a basis for decision-making in the current treatment of cognitive impairment in schizophrenia.

Major depressive disorder (MDD) is one of the most disabling illnesses, and approximately one-third of patients with MDD fail to show significant improvement after multiple courses of antidepressants, eventually progressing to treatment-resistant depression (TRD), a more severe and complex subtype that is difficult to treat. Obsessive-compulsive disorder (OCD) is a type of mental disorder characterized by repetitive obsessions and/or compulsive behaviors, and the high rate of comorbidity with other psychiatric disorders has been identified as a hallmark feature of OCD. In particular, OCD frequently co-occurs with MDD, and when these two conditions overlap, the resulting comorbidity is characterized by more severe symptoms and an increased risk of suicide. Magnetic seizure therapy (MST) is a novel, non-invasive neuromodulation technique that is safe and effective in the treatment of TRD with less cognitive impairment. This paper describes a case of significant symptom improvement following 100 Hz accelerated MST treatment in a patient with comorbid TRD and OCD. As a novel treatment option, MST requires further large-scale clinical trials to explore in the future.

Major depressive disorder (MDD) is one of the most disabling illnesses, and approximately one-third of patients with MDD fail to show significant improvement after multiple courses of antidepressants, eventually progressing to treatment-resistant depression (TRD), a more severe and complex subtype that is difficult to treat. Obsessive-compulsive disorder (OCD) is a type of mental disorder characterized by repetitive obsessions and/or compulsive behaviors, and the high rate of comorbidity with other psychiatric disorders has been identified as a hallmark feature of OCD. In particular, OCD frequently co-occurs with MDD, and when these two conditions overlap, the resulting comorbidity is characterized by more severe symptoms and an increased risk of suicide. Magnetic seizure therapy (MST) is a novel, non-invasive neuromodulation technique that is safe and effective in the treatment of TRD with less cognitive impairment. This paper describes a case of significant symptom improvement following 100 Hz accelerated MST treatment in a patient with comorbid TRD and OCD. As a novel treatment option, MST requires further large-scale clinical trials to explore in the future.

Objective:To explore the relationship between the clinical outcome of emotional symptoms and cognitive performance and related cerebral oxygenated hemoglobin in adolescents with depression.Methods:Through subject recruitment, 46 adolescent patients with depression (patient group) from the First Hospital of Shanxi Medical University were selected as the subjects for this study from December 2020 to December 2021, including 8 males and 38 females, aged 12-18 (15.7±2.3) years old. All patients received sertraline treatment for 8 weeks and were further followed into responders ( n=24) and non-responders ( n=22) according to the outcome of emotional symptoms. In the meantime, 51 healthy controls (control group) were enrolled, including 7 males and 44 females, aged 12-18 (16.1±1.5) years old. The repeatable battery for the assessment of neuropsychological status (RBANS) was conducted to measure the multi-dimensional neurocognitive performance, and the functional near-infrared spectroscopy (fNIRS) was used to assess changes in the concentration of oxyhemoglobin (HBO) during the verbal fluency test. The differences were compared in multi-dimensional cognitive performance and cerebral HBO level between each patient group and control group and between responders and non-responders. The changes were analyzed in cognitive performance and cerebral HBO level after intervention in responders and non-responders. Results:At baseline, compared to the control group, the patient group performed decreased scores of RBANS, immediate memory, speech function, attention, and delayed memory (88.0 (82.8, 100.0) M ( Q1, Q3) vs. 100.0 (90.0, 110.0) scores; 78.0 (73.0, 87.8) vs.85.0 (78.0, 94.0) scores; (84.4±16.1) vs. (95.7±15.7) scores; 106.0 (99.5, 115.0) vs.118.0 (109.0, 128.0) scores; 94.0 (84.5, 99.0) vs.97.0 (91.0, 101.0) scores), and lower HBO levels in 7 channels (all P<0.05). Compared to responders, non-responders showed more severe impairment of visual-spatial and attention performance (103.9±11.0 vs. 94.4±16.7 scores; 112.5±12.1 vs. 98.0±21.2 scores) ( t=2.30 or 2.87; all P<0.05). After treatment, the scores of RBANS and immediate memory improved significantly in responders (98.8±11.2 vs. 93.0±9.7 scores; 95.2±13.8 vs.83.0±14.6 scores) ( t=-3.00 or-4.97; both P<0.05), but the scores of attention and the HBO level of two channels in the prefrontal cortex were still significantly lower than those of the control group (Z=2.27, 3.02 or 3.04; all P<0.05). Besides, there were no significant differences in the scores of immediate memory and the HBO levels of 3 channels in the temporal lobe between the no-responders and the control group (all P>0.05). Conclusion:Immediate memory injure, attention injure and HBO levels of frontal-temporal lobes may be independent of emotional symptoms among adolescents with depression.

Cognitive impairment is one of the core features of schizophrenia and severely affects the prognosis of the disorder. Improving cognitive impairment is of great significance for alleviating symptoms, preventing relapses, enhancing the quality of life, and reducing the social burden in patients with schizophrenia. Based on the "Guidelines for the Assessment of Cognitive Impairment in Schizophrenia" published by the European Psychiatric Association in 2022, the article focuses on the intervention and management of cognitive impairment in schizophrenia patients following a systematic assessment, while also considering the specific context of practice in China. This paper reviews recent progress in cognitive impairment interventions for schizophrenia, providing clinical guidance across three key aspects: pharmacotherapy, physical therapy, and psychotherapy. Other interventions are also discussed. Additionally, it addresses the existing challenges and unresolved issues, aiming to provide a basis for decision-making in the current treatment of cognitive impairment in schizophrenia.